Market Synopsis

The global intussusception market 2020 is poised to reach USD 6.3 billion by 2023, at a CAGR of 4.4 % during the forecast period (2017-2023).

Market Scenario

In order to gain a fair amount of share in the market, businesses select different strategic tactics. The best approach to dominate the industry is product growth, as surgery is the definitive cure for the market for intussusception. The introduction of minimally invasive medicine and diagnostic approaches, such as computed tomography, has dramatically altered the market environment. In the developing regions of North America and Europe, the miniaturisation of surgical instruments and the advancement of minimum invasive procedures such as robotic laparoscopy are expected to push the future demand.

The global demand for intussusception is powered by advances in the surgery field, such as minimal invasive laparoscopy surgery. However, the drug industry is suffering from fragmentation of the industry, which has placed pressure on profit margins. The lack of patents and the spike in counterfeit products have also limited the development of the industry. The other industry limitations are high surgery costs and medical risks. Due to low invasive surgical procedures, the market is expected to see exponential growth over the review period.

Segmental Appraisal

Based on type, diagnosis, care, and end-user, the global market for intussusception has been segmented.

The industry has been segmented as Ileoileal, Ileocolic, Ileo-ileo-colic, and others, based on the form.

The market has been segmented, depending on the diagnosis, as barium enema, ultrasound, X-ray, computerised tomography ( CT), and others.

The industry has been segmented as surgery, medications, and others based on the surgery.

The industry has been segmented as hospitals & clinics, academia and research, and others, depending on the end consumer.

Regional Overview

Leading to the extensive amount of operations undertaken and heavy spending on health care, the Americas accounts for a substantial market share. Furthermore, the quickest adoption in the US of new drugs and surgical procedures pushes the demand for intussusception. In addition, the concentration of the major healthcare firms in this region's developing countries, combined with broad insurance penetration, is contributing steam to the growth of the sector. In comparison, the US is investing massively on healthcare, which also boosts the sale of intussusception therapy, accounting for 16 percent of overall GDP.

Thanks to high sales and heavy healthcare penetration, Europe is the world's second largest economy. Countries such as Germany and France are driving European market expansion. Over the evaluation period, the UK is projected to be the fastest growing country.

The Asia Pacific region is predicted to expand rapidly; China and India are expected to lead this market over the forecast period due to the rapidly increasing healthcare sector and significant unmet needs. Countries in South East Asia, such as Vietnam, Thailand and Malaysia, are expected to contribute significantly to the growth of the sector.

The Middle East & African sector is estimated to be dominated by gulf nations such as Saudi Arabia and the UAE. Kuwait, Jordan, Egypt and Iran are other Middle East nations to look out for. Due to weak economic and political conditions and poor development of healthcare, the African region is projected to see modest growth. The lack of populism has contributed to a lower degree of mass control, which is unable to claim higher public healthcare spending, which has limited the economy in sub-Saharan African countries.

Competitive Dashboard

Some of the key players profiled in the report are Pfizer, Inc., Carestream Health, Janssen Pharmaceuticals, Inc., Abbott, GlaxoSmithKline plc, sanofi-aventis U.S. LLC. , Novartis AG, FUJIFILM Holdings Corporation, Bayer AG, General Electric Company, Shimadzu Corporation, Bristol-Myers Squibb Company, and others.